EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY 4.0

Effects of bone marrow sparing radiotherapy on acute hematologic toxicity for patients with locoregionally advanced cervical cancer: a prospective phase II randomized controlled study

Wen Li, Lan Ma, Fang Li, Kemin Li, Yang Zhang, Hongtao Ren, Xing Bao, Yuyan Guo, Ya Guo, Mincong Wang, Dan Li, Yuanqiong Duan und 4 weitere

Radiation Oncology · 2024

DOI: 10.1186/s13014-024-02432-7 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Radiation Oncology, 2024. Verfasst von Wen Li und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, West China University Hospital 2, Sichuan University, 610041, Chengdu, China. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Radiotherapy, Intensity-Modulated, Leukopenia, Radiation Injuries. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Research and Development Projects of Shaanxi Province, Key Research and Development Project of Shaanxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate effects of bone marrow sparing (BMS) radiotherapy on decreasing the incidence of acute hematologic toxicity (HT) for locoregionally advanced cervical cancer (LACC) patients treated by pelvic irradiation. Materials and methods LACC patients were recruited prospectively from May 2021 to May 2022 at a single center and were evenly randomized into the BMS group and the control group. All patients received pelvic irradiation with concurrent cisplatin (40 mg/m2 weekly), followed by brachytherapy and BM V40 < 25% in the BMS group was additionally prescribed. Acute HT was assessed weekly. Binary logistic regression model and receiver operating characteristic (ROC) curve were used for predictive value analysis. The trial was registered with Chinese clinical trial registry (ChiCTR2200066485).

Results

A total of 242 patients were included in the analysis. Baseline demographic, disease and treatment characteristics were balanced between the two groups. In the intention-to-treat population, BMS was associated with a lower incidence of grade ≥ 2 and grade ≥ 3 acute HT, leukopenia and neutropenia s(72.70% v 90.90%, P < 0.001*; 16.50% vs. 65.30%, P < 0.001*; 66.10% vs. 85.10%, P = 0.001*; 13.20% vs. 54.50%, P < 0.001*; 37.20% vs. 66.10%, P < 0.001*; 10.70% vs. 43.80%, P < 0.001*). BMS also resulted in decreased dose delivered to the organs at risk (OARs) including rectum, bladder and left and right femoral head. Univariate and multivariate analyses showed that BM V40 was an independent risk factor for grade ≥ 3 acute HT (odds ratio [OR] = 2.734, 95% confidence interval [CI] = 1.959–3.815, P < 0.001*). Cutoff value was 25.036% and area under the curve (AUC) was 0.786. The nomogram was constructed, which was rigorously evaluated and internally cross-validated, showing good predictive performance.

Conclusions

Receiving BMS pelvic irradiation could reduce the incidence of acute HT in LACC patients, and BM V40 < 25% may be a significant factor in reducing the risks of acute HT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsRadiotherapy, Intensity-ModulatedLeukopeniaRadiation InjuriesFemaleHumansBone MarrowProspective StudiesRadiotherapy DosageCisplatinChemoradiotherapy

Stichwörter der Autor:innen

Bone marrow sparing (BMS)Cervical cancerHematologic toxicity (HT)Pelvic irradiation

Substanzen

Cisplatin

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, West China University Hospital 2, Sichuan University, 610041, Chengdu, China.
  • Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry Education, Sichuan University, 610041, Chengdu, China.
  • Department of Radiation Oncology, The Second Affiliated Hospital of Xi 'an Jiaotong University, Xi' An Jiao Tong University, 710004, Xi'An, China.
  • Department of Radiation Oncology, The Second Affiliated Hospital of Xi 'an Jiaotong University, Xi' An Jiao Tong University, 710004, Xi'An, China. yaliwang72@163.com.
  • Department of Obstetrics and Gynecology, West China University Hospital 2, Sichuan University, 610041, Chengdu, China. yrtt2013@163.com.
  • Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry Education, Sichuan University, 610041, Chengdu, China. yrtt2013@163.com.

Förderung

  • Key Research and Development Projects of Shaanxi Province
  • Key Research and Development Project of Shaanxi Province

Zitieren

APA

Li, W., Ma, L., Li, F., Li, K., Zhang, Y., Ren, H., Bao, X., Guo, Y., Guo, Y., Wang, M., Li, D., Duan, Y., Ma, X., Wang, Z., Wang, Y., & Yin, R. (2024). Effects of bone marrow sparing radiotherapy on acute hematologic toxicity for patients with locoregionally advanced cervical cancer: a prospective phase II randomized controlled study. Radiation Oncology. https://doi.org/10.1186/s13014-024-02432-7

Vancouver

Li W, Ma L, Li F, Li K, Zhang Y, Ren H, et al. Effects of bone marrow sparing radiotherapy on acute hematologic toxicity for patients with locoregionally advanced cervical cancer: a prospective phase II randomized controlled study. Radiation Oncology. 2024. doi:10.1186/s13014-024-02432-7

BibTeX
@article{Li2024,
  author = {Li, Wen and Ma, Lan and Li, Fang and Li, Kemin and Zhang, Yang and Ren, Hongtao and Bao, Xing and Guo, Yuyan and Guo, Ya and Wang, Mincong and Li, Dan and Duan, Yuanqiong and Ma, Xiulong and Wang, Zhongwei and Wang, Yali and Yin, Rutie},
  title = {Effects of bone marrow sparing radiotherapy on acute hematologic toxicity for patients with locoregionally advanced cervical cancer: a prospective phase II randomized controlled study},
  journal = {Radiation Oncology},
  year = {2024},
  doi = {10.1186/s13014-024-02432-7}
}
Kostenlos starten →